PRAME抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P08642(PRAME Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The PRAME (PReferentially expressed Antigen in MElanoma) antibody is a diagnostic tool used to detect the PRAME protein, a cancer/testis antigen encoded by the *PRAME* gene. PRAME is normally expressed in testicular germ cells and placenta but is silenced in most healthy adult tissues. However, it becomes aberrantly overexpressed in various malignancies, including melanoma, leukemia, sarcoma, breast, lung, and ovarian cancers. This tumor-specific expression profile makes PRAME a valuable biomarker for cancer diagnosis and research.

PRAME antibodies are widely used in immunohistochemistry (IHC) to identify PRAME protein in tumor tissue samples. In melanoma, PRAME helps distinguish malignant lesions from benign nevi, as it is highly expressed in melanoma but absent or low in most benign melanocytic proliferations. It also aids in diagnosing other PRAME-positive tumors and monitoring minimal residual disease. Compared to traditional markers like S100 or HMB-45. PRAME exhibits higher specificity in certain contexts, particularly for metastatic melanoma.

Beyond diagnostics, PRAME's role in tumorigenesis—such as repressing retinoic acid signaling to promote cell proliferation—has spurred interest in its therapeutic targeting. PRAME antibodies also support research into its prognostic value, as overexpression often correlates with aggressive disease and poor outcomes. Ongoing studies explore PRAME as a potential immunotherapeutic target for vaccines or CAR-T therapies.